Ovarian cancer (OC) is considered a heterogeneous disease usually diagnosed at late stages as there are no symptoms and signs. Hallmarks and heterogeneity of ovarian cancer are limited and hard to establish according to the experiments in vitro models. Surgery, chemotherapy and other traditional treatments are accompanied by many toxic side effects. This study aimed to evaluate the anticancer activity of organoselenium compounds against sensitive cells A2780, cisplatin-resistant cells (A2780CP) and SKOV-3 cells. ((diselanediylbis (4,1-phenylene)) bis (azanediyl)) bis(3-methyl-1-oxobutane-1,2-diyl) diacetate, Compound 16, showed anticancer activity through changing the cell morphology and inhibit cell proliferation and this was confirmed by using MTT (3-(4,5-dimethylthiazoyl)-2,5-diphenyl-tetrazolium bromide(.